Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials

BACKGROUND: Antibodies targeting the programmed death‐ligand 1 (PD‐L1)/programmed cell death protein 1 (PD‐1) checkpoint may cause adverse events (AEs) that are linked to the mechanism of action of this therapeutic class and unique from those observed with conventional chemotherapy. METHODS: Patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelly, Karen, Infante, Jeffrey R., Taylor, Matthew H., Patel, Manish R., Wong, Deborah J., Iannotti, Nicholas, Mehnert, Janice M., Loos, Anja H., Koch, Helga, Speit, Isabell, Gulley, James L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947549/
https://www.ncbi.nlm.nih.gov/pubmed/29469949
http://dx.doi.org/10.1002/cncr.31293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947549/
https://www.ncbi.nlm.nih.gov/pubmed/29469949
http://dx.doi.org/10.1002/cncr.31293

Ejemplares similares